About this trial
The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone.
A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone.
The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≥ 18 years of age
Undergoing chemotherapy and experiencing nausea despite adherence to the prescribed antiemetic regimen
Understands and speaks Danish
Written and orally informed consent
Disqualifiers
Brain metastases
Performance status >2
Trial design
Crossover
Treatments tested in this trial
Holistic acupuncture and acupressure
Other interventionThe intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding. Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure. A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes.
Standard medical treatment
Other interventionStandard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.
Treatment groups
Trial outcomes
Primary outcomes
Patient reported nausea assessed on the EORTC-15-PAL Scale
Secondary outcomes
Patient reported symptom intensity according to the EORTC-15 PAL Scale
Other outcomes
Patient reported use of antiemetic medicine
Sponsors and contacts
Click on the lead sponsor to view all of their trials.